Last reviewed · How we verify
Prevention of blood clots after heart attack or stroke — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Plavix | clopidogrel | Generic (originally Sanofi/BMS) | Thienopyridine antiplatelet agent | Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter | 1997-11-17 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Sanofi/BMS) · 1 drug in Prevention of blood clots after heart attack or stroke
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of blood clots after heart attack or stroke:
- Prevention of blood clots after heart attack or stroke treatment updates — RSS
- Prevention of blood clots after heart attack or stroke treatment updates — Atom
- Prevention of blood clots after heart attack or stroke treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of blood clots after heart attack or stroke — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-blood-clots-after-heart-attack-or-stroke. Accessed 2026-06-10.
Related
- Prevention of blood clots after heart attack or stroke full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing